WolverineBlend
BPC-157 + TB-500 recovery stack in a single vial.
- Status
- Research / not approved
- Developer
- Compounded research-peptide blend; vendor-specific
- Receptors / target
- Not a single target — combines BPC-157 (cytoprotective pentadecapeptide) and TB-500 (thymosin-beta-4 fragment; actin regulation & angiogenesis); no characterized combined pharmacology
- FDA-approved?
- NO
- Prescription available?
- NO
- Studied for
- tendon, ligament & muscle repairgut / GI protectionangiogenesiswound healing & recovery
Overview
Wolverine is a compounded research-peptide blend combining BPC-157 and TB-500, the two most popular "healing/recovery" research peptides, in a single vial (some vendors offer a "Wolverine Plus" that adds KPV). It is named for regeneration and marketed toward tissue repair, but it is sold research-use-only, is not an approved drug, and has no clinical trials as a combination.
Mechanism
The two peptides act through distinct, complementary pathways. BPC-157 is a synthetic gastric pentadecapeptide studied for soft-tissue and gut repair via nitric-oxide and growth-factor signaling and angiogenesis. TB-500 is a synthetic thymosin-beta-4 fragment that promotes cell migration and angiogenesis through actin regulation. The blend's rationale is additive coverage of overlapping repair processes, but the pharmacology of the two combined in one injection has not been characterized.
Clinical evidence
There are no human clinical trials of the Wolverine blend — efficacy rests on the individual components, and that evidence is overwhelmingly preclinical. BPC-157's literature is almost entirely animal (rat tendon, ligament, muscle and gut models); the regeneration evidence for thymosin-beta-4 / TB-500 is likewise animal and in-vitro, with no controlled human injectable data, and commercial "TB-500" is typically a fragment of the parent protein. No peer-reviewed evidence supports the specific combination, its dosing, or claimed synergy.
Safety profile
The combined-injection safety of Wolverine has not been studied, and both components lack robust human safety data and remain unapproved investigational compounds. TB-500 (thymosin beta-4) is prohibited in sport by WADA at all times, and BPC-157 is also treated as an anti-doping concern, so this blend is banned in sport. Reported effects are mostly local (injection-site reactions) with limited long-term human data. Research-use only; not FDA-approved for any use, and nothing here is therapeutic or dosing guidance.
- Weeks 1–8
No human data for the blend. Both components' healing claims come from animal/anecdotal sources over weeks; TB-500 is prohibited in sport.
Reported in published literature and user reports. Not a complete list, and not medical advice.
- Injection-site reactions
- Limited human safety data for either component
- Unstudied combined-injection safety
If severe or unexpected symptoms occur, contact a qualified medical professional. PEPTIDES·INDEX does not provide medical advice.
- Human contraindication data for the BPC-157 + TB-500 blend do not exist; combined-injection safety is unstudied
- Theoretical caution in active or prior malignancy given the pro-angiogenic activity of both components (angiogenesis could theoretically support tumor growth)
- Prohibited in sport by WADA — not suitable for tested athletes
- No documented human drug interactionsInteraction profile uncharacterized in humans (research use only)
Compare
- vs BPC-157
The standalone cytoprotective pentadecapeptide in the blend; better studied (though still preclinical) and not the WADA-banned half.
- vs GLOW
A related repair blend pairing GHK-Cu with BPC-157 and TB-500; also WADA-prohibited via TB-500.
- vs KLOW
An extended repair/recovery blend (adds KPV and GHK-Cu); shares the unstudied-combination and TB-500 doping concerns.
FAQ
Is there clinical evidence for the Wolverine blend?
No. There are no human clinical trials of the Wolverine (BPC-157 + TB-500) blend. Efficacy rests on the individual components, and that evidence is overwhelmingly preclinical — almost entirely animal and in-vitro models, with no controlled human injectable data and no support for the specific combination or claimed synergy.
Is Wolverine banned in sport?
Yes. TB-500 (thymosin beta-4) is prohibited in sport by WADA at all times, and BPC-157 is also treated as an anti-doping concern, so this blend is banned for tested athletes.
What are the safety concerns?
Combined-injection safety has not been studied, and both components lack robust human safety data and remain unapproved investigational compounds. Reported effects are mostly local (injection-site reactions), with limited long-term human data.
What is in the Wolverine blend?
It combines the two most popular 'healing/recovery' research peptides — BPC-157 (a synthetic gastric pentadecapeptide) and TB-500 (a synthetic thymosin-beta-4 fragment) — in a single vial. Some vendors offer a 'Wolverine Plus' that also adds KPV. Composition is vendor-specific, not standardized.
Is Wolverine FDA-approved?
No. Neither component is an approved drug; both remain unapproved investigational compounds, and the blend is sold research-use-only. It has not been evaluated by the FDA for any use.
How does Wolverine compare to BPC-157 alone?
BPC-157 on its own is the better-studied half (though still only preclinical) and is not the WADA-banned component. Adding TB-500 makes the blend WADA-prohibited and introduces a second compound with even less human data, without any trial showing the combination outperforms either peptide alone.
Similar compounds
Starting references for the library summary. These are not dosing instructions or medical advice.
For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.